Rheum Nurse Nwsl Vol 4, Iss3 Post-Test

RHEUMATOLOGY NURSE NEWSLETTER VOLUME 4, ISSUE 3
ACTIVITY LEARNING ASSESSMENT REQUEST FOR CREDIT & EVALUATION FORM

Simply complete the following survey, which will be reviewed by Institute educators upon receipt.

Activity Instructions & Criteria for Success

Continuing Nursing Education contact hours are offered to all activity participants. To successfully complete this activity and obtain a Certificate of Contact Hours awarded, the learner is required to read the entire newsletter, complete the post-test, and complete the activity evaluation form. Learners are required to correctly answer 80% of the learning assessment questions. Statements of Credit will be forwarded via email within 4 to 6 weeks. All forms must be received by December 15, 2013, to be eligible for credit.

Question Title

* 1. Which of the following biologic agents is FDA-approved for the treatment of ANCA-associated vasculitis?

Adalimumab

Rituximab

Certolizumab pegol

Anakinra

Question Title

* 2. Joanna R. is a 25-year-old female who recently had her first child and has been breastfeeding for 3 months. Of the following choices, which would be the safest to prescribe to manage her RA-related symptoms while she continues to breastfeed?

Etanercept

Leflunomide

Sulfasalazine

Methotrexate

Question Title

* 3. At what gestational stage does the risk of NSAID use increase?

After 20 weeks of gestation

After 24 weeks of gestation

After 28 weeks of gestation

After 30 weeks of gestation

Question Title

* 4. Which of the following factors are most commonly associated with the onset of digital ulcers in patients newly presenting with systemic sclerosis?

Hispanic ethnicity

Family history of systemic sclerosis

Younger age

Female gender

Question Title

* 5. James R. is a patient with severe RA who has failed 3 previous biologic therapies, including 2 anti-TNFs, and is now being started on abatacept. According to published Treat to Target guidelines, which would be the most appropriate target for his treatment?

Remission

Low disease activity

Moderate disease activity

Treat to target guidelines don’t address patients with severe disease

Question Title

* 6. According to a recent study by Beard et al, approximately what percentage of discussion about medication costs of drugs indicated for the treatment of RA are initiated by healthcare providers?

25%

50%

65%

80%

Question Title

* 7. Based on recent research, which of the following patients would be least likely to be adherent to their treatment regimen for RA?

A 55-year-old CEO of a Fortune 500 company

A 25-year-old sedentary, unemployed male with health coverage under his parents’ insurance

A 64-year-old retired grandmother

A 30-year-old father of 2 who works two jobs to pay the bills

Question Title

* 8. According to published Treat to Target guidelines, which disease activity measure is the preferred choice in the clinical care of RA?

DAS28

RAPID3

CDAI

There is no preferred disease activity measure indicated within the guidelines

Question Title

* 9. Which of the following side effects are not among the most common reasons that patients discontinue use of antidepressants?

Loss of appetite

Weight gain

Sexual dysfunction

Sleep disturbance

Question Title

* 10. In what way can Wegener’s granulomatosis with polyangiitis (WG) be differentiated from other respiratory tract infections?

It begins in the small vessels and tissues of the lungs only

It occurs in the absence of infectious organisms

Patients with WG typically do not wheeze

It begins in the small vessels and tissues of the sinuses only

Question Title

* 11. After participating in this activity, I am better able to:

	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
Discuss common factors that lead to nonadherence to treatment regimens for rheumatoid arthritis, including cost of medication, side effects profiles, and poor clinician-patient communication	Discuss common factors that lead to nonadherence to treatment regimens for rheumatoid arthritis, including cost of medication, side effects profiles, and poor clinician-patient communication Strongly disagree	Discuss common factors that lead to nonadherence to treatment regimens for rheumatoid arthritis, including cost of medication, side effects profiles, and poor clinician-patient communication Disagree	Discuss common factors that lead to nonadherence to treatment regimens for rheumatoid arthritis, including cost of medication, side effects profiles, and poor clinician-patient communication Neutral	Discuss common factors that lead to nonadherence to treatment regimens for rheumatoid arthritis, including cost of medication, side effects profiles, and poor clinician-patient communication Agree	Discuss common factors that lead to nonadherence to treatment regimens for rheumatoid arthritis, including cost of medication, side effects profiles, and poor clinician-patient communication Strongly agree
Analyze factors that may lead to increasing levels of depression and catastrophizing in patients with rheumatic disease	Analyze factors that may lead to increasing levels of depression and catastrophizing in patients with rheumatic disease Strongly disagree	Analyze factors that may lead to increasing levels of depression and catastrophizing in patients with rheumatic disease Disagree	Analyze factors that may lead to increasing levels of depression and catastrophizing in patients with rheumatic disease Neutral	Analyze factors that may lead to increasing levels of depression and catastrophizing in patients with rheumatic disease Agree	Analyze factors that may lead to increasing levels of depression and catastrophizing in patients with rheumatic disease Strongly agree
Identify characteristics that differentiate rare autoimmune diseases such as Wegener’s granulomatosis with polyangiitis from more common conditions	Identify characteristics that differentiate rare autoimmune diseases such as Wegener’s granulomatosis with polyangiitis from more common conditions Strongly disagree	Identify characteristics that differentiate rare autoimmune diseases such as Wegener’s granulomatosis with polyangiitis from more common conditions Disagree	Identify characteristics that differentiate rare autoimmune diseases such as Wegener’s granulomatosis with polyangiitis from more common conditions Neutral	Identify characteristics that differentiate rare autoimmune diseases such as Wegener’s granulomatosis with polyangiitis from more common conditions Agree	Identify characteristics that differentiate rare autoimmune diseases such as Wegener’s granulomatosis with polyangiitis from more common conditions Strongly agree
Develop strategies to manage women with progressive disease who prioritize pregnancy over management of their worsening symptoms	Develop strategies to manage women with progressive disease who prioritize pregnancy over management of their worsening symptoms Strongly disagree	Develop strategies to manage women with progressive disease who prioritize pregnancy over management of their worsening symptoms Disagree	Develop strategies to manage women with progressive disease who prioritize pregnancy over management of their worsening symptoms Neutral	Develop strategies to manage women with progressive disease who prioritize pregnancy over management of their worsening symptoms Agree	Develop strategies to manage women with progressive disease who prioritize pregnancy over management of their worsening symptoms Strongly agree

Question Title

* 12. Relative to each objective, do you plan to change your practice?

	Yes	No	Already Doing
Discuss common factors that lead to nonadherence to treatment regimens for rheumatoid arthritis, including cost of medication, side effects profiles, and poor clinician-patient communication	Discuss common factors that lead to nonadherence to treatment regimens for rheumatoid arthritis, including cost of medication, side effects profiles, and poor clinician-patient communication Yes	Discuss common factors that lead to nonadherence to treatment regimens for rheumatoid arthritis, including cost of medication, side effects profiles, and poor clinician-patient communication No	Discuss common factors that lead to nonadherence to treatment regimens for rheumatoid arthritis, including cost of medication, side effects profiles, and poor clinician-patient communication Already Doing
Analyze factors that may lead to increasing levels of depression and catastrophizing in patients with rheumatic disease	Analyze factors that may lead to increasing levels of depression and catastrophizing in patients with rheumatic disease Yes	Analyze factors that may lead to increasing levels of depression and catastrophizing in patients with rheumatic disease No	Analyze factors that may lead to increasing levels of depression and catastrophizing in patients with rheumatic disease Already Doing
Identify characteristics that differentiate rare autoimmune diseases such as Wegener’s granulomatosis with polyangiitis from more common conditions	Identify characteristics that differentiate rare autoimmune diseases such as Wegener’s granulomatosis with polyangiitis from more common conditions Yes	Identify characteristics that differentiate rare autoimmune diseases such as Wegener’s granulomatosis with polyangiitis from more common conditions No	Identify characteristics that differentiate rare autoimmune diseases such as Wegener’s granulomatosis with polyangiitis from more common conditions Already Doing
Develop strategies to manage women with progressive disease who prioritize pregnancy over management of their worsening symptoms	Develop strategies to manage women with progressive disease who prioritize pregnancy over management of their worsening symptoms Yes	Develop strategies to manage women with progressive disease who prioritize pregnancy over management of their worsening symptoms No	Develop strategies to manage women with progressive disease who prioritize pregnancy over management of their worsening symptoms Already Doing

Question Title

* 13. How much influence do you feel that rheumatology nurses can have on a patient’s
overall adherence to their prescribed treatment for RA?

Significant influence; if we educate patients properly on the risks and benefits of their medication, they will usually adhere to therapy

Moderate influence; we do our best, but there are often factors beyond our control that affect adherence rates

Limited influence; patients will usually do what they want regardless of what we tell them

Question Title

* 14. What is your primary practice setting?

Hospital

University/academic medical center

Clinic

Private practice

Group or staff model health maintenance organization

Other (please specify)

Question Title

* 15. How many years have you been in practice as a rheumatology nurse?

0-5 years

6-10 years

11-15 years

16 or more years

Question Title

* 16. Was disclosure information provided to you at the beginning of this activity?

Yes

Question Title

* 17. Did this activity promote a particular company or product?

Yes

If yes, please explain in detail

Question Title

* 18. Number of credits claimed (Maximum credits=1.3 ANCC-COA contact hours/1.5 California Board of Nursing contact hours)

	Please choose one
Contact hours requested	Contact hours requested Please choose one menu

Question Title

* 19. Please choose the appropriate degree

	Please choose one
Degree	Degree Please choose one menu

Other (please specify)

Question Title

* 20. Please enter the following information

Name

Address:

City/Town:

State:

ZIP:

Email Address:

Phone Number:

Question Title

* 1. Which of the following biologic agents is FDA-approved for the treatment of ANCA-associated vasculitis?

Question Title

* 2. Joanna R. is a 25-year-old female who recently had her first child and has been breastfeeding for 3 months. Of the following choices, which would be the safest to prescribe to manage her RA-related symptoms while she continues to breastfeed?

Question Title

* 3. At what gestational stage does the risk of NSAID use increase?

Question Title

* 4. Which of the following factors are most commonly associated with the onset of digital ulcers in patients newly presenting with systemic sclerosis?

Question Title

* 5. James R. is a patient with severe RA who has failed 3 previous biologic therapies, including 2 anti-TNFs, and is now being started on abatacept. According to published Treat to Target guidelines, which would be the most appropriate target for his treatment?

Question Title

* 6. According to a recent study by Beard et al, approximately what percentage of discussion about medication costs of drugs indicated for the treatment of RA are initiated by healthcare providers?

Question Title

* 7. Based on recent research, which of the following patients would be least likely to be adherent to their treatment regimen for RA?

Question Title

* 8. According to published Treat to Target guidelines, which disease activity measure is the preferred choice in the clinical care of RA?

Question Title

* 9. Which of the following side effects are not among the most common reasons that patients discontinue use of antidepressants?

Question Title

* 10. In what way can Wegener’s granulomatosis with polyangiitis (WG) be differentiated from other respiratory tract infections?

Question Title

* 11. After participating in this activity, I am better able to:

Question Title

* 12. Relative to each objective, do you plan to change your practice?

Question Title

* 13. How much influence do you feel that rheumatology nurses can have on a patient’soverall adherence to their prescribed treatment for RA?

Question Title

* 14. What is your primary practice setting?

Question Title

* 15. How many years have you been in practice as a rheumatology nurse?

Question Title

* 16. Was disclosure information provided to you at the beginning of this activity?

Question Title

* 17. Did this activity promote a particular company or product?

Question Title

* 18. Number of credits claimed (Maximum credits=1.3 ANCC-COA contact hours/1.5 California Board of Nursing contact hours)

Question Title

* 19. Please choose the appropriate degree

Question Title

* 20. Please enter the following information

* 13. How much influence do you feel that rheumatology nurses can have on a patient’s
overall adherence to their prescribed treatment for RA?